Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of June 2018, with the report dated June 19, 2018. The filing serves to incorporate by reference a press release regarding an update on the Company's Phase II clinical trial for its drug candidate, Namodenoson, in the treatment of advanced hepatocellular carcinoma in patients whose disease has progressed on sorafenib therapy.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on clinical trial updates and does not contain financial statements or quantitative financial data.
Material Changes
The material change reported is the issuance of a press release on June 19, 2018, providing an update on the Phase II clinical trial of Namodenoson. The filing does not detail specific trial results or statistical changes within the text provided, only the existence of the update.
Guidance, Outlook, and Risks
The filing incorporates "Forward Looking Statements" from the attached press release by reference into the Company's Registration Statements on Form F-3. No specific guidance, outlook, or detailed risk factors are explicitly described in the body of this Form 6-K text.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (Press Release dated June 19, 2018) for specific details on the Namodenoson Phase II trial update.
- Verify the status of the clinical trial for advanced hepatocellular carcinoma in patients progressing on sorafenib therapy.
- Check subsequent filings for any superseding information regarding the trial results or forward-looking statements.